Dapiglutide

GLP-1 and GLP-2 are both proglucagon products but do very different things: GLP-1 handles glycaemia and satiety, while GLP-2 is trophic to the intestinal epithelium, increasing villus height, crypt depth and tight-junction integrity - the mechanism behind teduglutide in short bowel syndrome. Dapiglutide activates both, and the hypothesis is that reducing intestinal permeability lowers the endotoxin-driven low-grade inflammation that accompanies obesity, while the GLP-1 arm does the conventional metabolic work. Early clinical data have shown weight loss plus reductions in inflammatory markers, but this is still small-scale evidence.

Targets: GLP-1 receptor, GLP-2 receptor

• · Early-phase escalating weekly doses; specific maintenance milligram figures have not been published in a form worth quoting.

Work out your exact syringe units →

• commonNausea— GLP-1 arm effect.
• commonGastrointestinal upset
• rareTheoretical intestinal polyp or neoplasia risk— GLP-2 agonists are trophic to intestinal epithelium; teduglutide labelling requires colonoscopic surveillance for this reason.

• Active gastrointestinal malignancy or history of colorectal neoplasia - the GLP-2 arm is growth-promoting to gut epithelium.
• Pregnancy.
• Very limited human safety data overall.

• redundantsemaglutide — GLP-1 agonism already present.
• redundantbpc-157 — Both are pitched at gut barrier repair, though by entirely different mechanisms and with very different evidence bases.

• · Weight.
• · Inflammatory markers such as hsCRP.
• · Colonoscopic surveillance would be expected for chronic GLP-2 agonism.

Investigational; not approved anywhere.

• Zealand Pharma dapiglutide phase 1b/2a disclosures (other)

Dapiglutide is the only compound in this class targeting GLP-2, and the rationale is worth understanding even though the evidence is thin. GLP-2 is the other proglucagon-derived peptide released from intestinal L-cells alongside GLP-1, and its physiological job is trophic: it increases intestinal crypt cell proliferation, villus height, mucosal blood flow and tight-junction integrity. The therapeutic hypothesis is that obesity involves increased intestinal permeability, that translocated bacterial products drive low-grade systemic inflammation, and that restoring gut barrier function attacks a driver of metabolic disease that no other obesity drug touches. Early-phase human data reported weight loss plus reductions in inflammatory markers, which is consistent with the hypothesis without demonstrating it - weight loss alone lowers inflammatory markers. GLP-2 agonism is an established therapeutic principle in a different setting (teduglutide for short bowel syndrome), so the receptor pharmacology is not speculative; what is speculative is whether gut barrier restoration does anything useful in obesity. There is also an obvious safety question that the short-bowel experience raises: GLP-2 is trophic to intestinal mucosa, and trophic effects on a proliferating epithelium over years is exactly the kind of thing that needs long-term colonoscopic surveillance data before anyone should be relaxed about it.

The evidence base is thin enough that the honest summary is: interesting hypothesis, early human data, nothing established. Anyone buying dapiglutide from a research vendor is buying an unverifiable peptide for an unproven mechanism. The specific safety question that deserves attention if this ever becomes a real drug is the trophic effect of chronic GLP-2 agonism on intestinal epithelium.

• GLP-1 receptor (GLP1R) — Not verified

  Appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion.

• GLP-2 receptor (GLP2R) — Not verified

  Intestinal mucosal growth, improved tight-junction integrity and reduced intestinal permeability, with a hypothesised downstream reduction in metabolic endotoxaemia and systemic inflammation.

Weight and inflammatory-marker changes were reported over 8-16 weeks in early trials. Nothing beyond that is characterised.

Contains a full GLP-1 arm, so redundant with the incretins. There is no legitimate supply. The GLP-2 arm is the only genuinely novel element and there is no data on combining it with anything.

Against every other compound here: dapiglutide is the only one targeting gut barrier function, and it is also the one with the least human evidence. As a weight drug it has nothing to recommend it over the incretins. Its interest is entirely in whether the gut-barrier-inflammation axis turns out to matter.

Investigational; no legitimate supply and no price.

• ?No peer-reviewed clinical publication could be resolved and verified in this session, so the single citation is marked unverified.
• ?No pharmacokinetic parameters of any kind are available.
• ?The gut-barrier-to-inflammation-to-metabolic-disease causal chain is hypothesised, not demonstrated in humans.
• ?Long-term intestinal safety of chronic GLP-2 agonism in a non-short-bowel population is uncharacterised.
• ?No trial identifiers, participant numbers or durations were verified, so the trial list is left empty rather than populated from memory.

• Dapiglutide phase 1b/2a in obesity (Zealand Pharma)

  Further reading rather than evidence. Early-phase human results have been presented and communicated by the sponsor, but no peer-reviewed dapiglutide clinical publication could be resolved and verified in this session.